Study design and participants
anxiety, epilepsy, PCOS, polycystic ovary syndrome, depression, hypertension, diabetes
POLYCYSTIC OVARIES, THYROID DISEASE, EPILEPSY, DYSFUNCTION, POLYCYSTIC OVARY SYNDROME, SECONDARY, IRON DEFICIENCY ANEMIA, HYPERANDROGENISM, HYPERTENSION, DIABETES
This randomized controlled trial with was performed in a parallel design on 84 patients with polycystic ovary syndrome referred to Al-Zahra Hospital in Tabriz-Iran, from July 2021 to October 2021.Inclusion criteria included a minimum of secondary education, diagnosis of polycystic ovary syndrome by a gynecologist (hyperandrogenism, ovulatory dysfunction, and polycystic ovaries), and a medical record of PCOS. Exclusion criteria included having a history of mental illness according to the person’s statement, hypertension, iron deficiency anemia, diabetes, thyroid disease, epilepsy, pregnant and postpartum women.In this study, the sample size was calculated based on both depression and anxiety variables using G-Power software. Based on the results of the study by Mehrabadi et al. (2018) [